Skip to main content
MedPathMedPath Home
Clinical Trials/CTRI/2023/08/055977
CTRI/2023/08/055977
Not yet recruiting
Phase 2

A Randomized placebo controlled trial to evaluate the efficacy Of Parikara Yoga and Pathya in the Management of Yakrita Roga with special reference to Non-Alcoholic Fatty Liver Disease. - NI

ational Institute of Ayurveda Deemed to be University, Jaipur0 sites0 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsHealth Condition 1: K760- Fatty (change of) liver, not elsewhere classifiedHealth Condition 2: K760- Fatty (change of) liver, not elsewhere classifiedHealth Condition 3: K77- Liver disorders in diseases classified elsewhere

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Health Condition 1: K760- Fatty (change of) liver, not elsewhere classifiedHealth Condition 2: K760- Fatty (change of) liver, not elsewhere classifiedHealth Condition 3: K77- Liver disorders in diseases classified elsewhere
Sponsor
ational Institute of Ayurveda Deemed to be University, Jaipur
Status
Not yet recruiting
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Sponsor
ational Institute of Ayurveda Deemed to be University, Jaipur

Eligibility Criteria

Inclusion Criteria

  • •1\. Patients of either sex of age group \>18years and \<60 years with USG
  • •finding suggestive of fatty liver grade 1,2 and 3\.
  • •2\.Non\-Alcoholic or patients with history of alcohol addiction less than 20gm
  • •per day in men and 10 gm per day in women.
  • •3\. Clinical sign and symptoms suggesting of Yakrita Roga/NAFLD that is,
  • •pain in right upper quadrant/ epigastric region of abdomen, feeling of nausea,
  • •heaviness in abdomen, flatulence ,loss of appetite and burning sensation in
  • •abdomen if any.
  • •4\. Patients with normal serum bilirubin level and ALT/AST level less than 1\.5
  • •times of normal limit.

Exclusion Criteria

  • •1\. Pregnant and lactating women.
  • •2\. Patients with history of diabetes mellitus, autoimmune hepatitis, drug
  • •abuse, chronic Hepatitis, raised ALT/AST level more than 1\.5 times of
  • •normal limit.
  • •3\. Patients with complications of metabolic syndrome such as
  • •cerebrovascular accident, myocardial infarction, chronic kidney diseases,
  • •suffering from cirrhosis, ascites, variceal haemorrhage, coagulopathy,
  • •hepatorenal syndrome
  • •4\. Patient have any kind of malignancy.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Not yet recruiting
Phase 2
Evaluate the effect of hartaki churna with buttermilk in metabolic syndrome
CTRI/2024/03/064745ational Institute of Ayurveda Jaipur
Recruiting
Phase 4
A randomised trial of krill oil for osteoarthritis of the knee
ACTRN12616000726459niversity of Tasmania260
Recruiting
Phase 2
Safety Assessment of Two Popular Legal Party Drugs: BZP and BZP+TFMPPSubjects who have used BZP or BZP+TFMPP on at least 3 previous occasionsOther -
ACTRN12606000504516Ministry of Health New Zealand24
Active, not recruiting
Not Applicable
Smoking cessatio
EUCTR2012-002731-28-PLBioprojet250
Active, not recruiting
Not Applicable
Smoking cessatioSmoking cessationMedDRA version: 16.1Level: LLTClassification code 10008374Term: Cessation of smokingSystem Organ Class: 100000004869Therapeutic area: Psychiatry and Psychology [F] - Behaviours [F01]
EUCTR2012-002731-28-CZBioprojet350